Additional file 2: Table S1. of GMP-conformant on-site manufacturing of a CD133+ stem cell product for cardiovascular regeneration

Overview of data obtained from CliniMACS® Prodigy BM-133 System validation process (a) and product quality review (PQR) (b). Volumes of samples were ascertained by visual control (bone marrow (BM)) or by weighing (cell product (CP), non-target cell bag (NTCB), waste bag (WB)). Total numbers of viable CD45+ and CD133+ cells were calculated by multiplying absolute cell numbers per volume unit with corresponding volumes. The frequencies of viable CD133+ cells were measured by flow cytometry in accordance with ISHAGE guidelines. (DOC 42 kb)